Our science

Ladon Therapeutics brings together breakthrough peptide chemistry and a state of the art diagnostic laboratory from gene expression profiling to in vivo disease models to characterize, test and evaluate ixPeptide® drug candidates.

Contact Us

Our vision is to be a pioneering bio-pharmaceutical company that cures debilitating diseases through breakthrough scientific innovations.

Gábor Heltovics
Chief Executive Officer

The ixPeptide® Platform

Molecular solution to increase the “druggability” potential of peptidic compounds

Pharmacologically active peptides are a unique class of compounds with molecular weights from 300 to 5000 Da. They are considered as linear polymers of natural and/or artificial amino acids.

Pharmacologically active peptides face major hurdles to become drugs:

Considerable 3D structural instability at short chain-length. This limits their receptor binding potential.

Short half-life under physiological conditions due to intestinal proteolytic enzyme decomposition and rapid liver metabolization

Low membrane penetration potential. Contrary to small organic drug molecules, the limited passive movement of peptides through biological membranes prohibits their effective binding to intracellular targets.

What we do

The ixPeptide® Platform offers a breakthrough solution to overcome these drawbacks and increase the drug-likeness of the peptide molecule to be developed

The ixPeptide® Platform

The ixPeptide Platform is a breakthrough molecular solution for the custom design of selfassemling polypeptides. It increases the drug-likeness of the peptide molecules and creates first-in-class medicines to treat patients with major unmet clinical needs

Pharmacologically active peptides*

Considerable 3D structural instability at short chain-lenght.
this limits their receptor binding potential.

Short half-life under physiological conditions due to intestinal proteolytic enzyme decomposition and rapid liver metabolization.

Low membrane penetration potential.
Contrary to small organic drug molecules, the limited passive movement of peptides through biological membranes prohibits their effective binding to intracellular targets.​

*Pharmacologically active peptides are a unique class of compounds with molecular weights from 300 to 5000 Da. They are considered as linear polymers of natural and/or artificial amino acids.​

ixPeptide®

The introduction of artificial amino acids enhances the stability of the 3D conformation. This results in an entropically more favored receptor binding profile.​

Longer half-life under physiological condition due to the resistance to trypsin digestion

The introduction of positively charged residues in combination with a restricted secondary structure enables cell-membrane penetration.​

High throughput ixPeptide® platform

HT based peptide synthesis and target identification & validation significantly reduce time to select lead candidates for drug development.

Robotized, automated synthesis

AI Computational design

Robotized synthesis

Automated purifiction

Target validation

Gene expression analysis​

Protein expression analysis​

Histology​

Immunohistochemistry​

Immunofluorescent staining​

2D cell culture models

3D organoid culture models​

Signal transduction pathways​

In vitro disease modelling​

In vivo disease modelling​

In vivo drug distribution analysis

Design by AI

The ixPeptide® Platform also utilizes AI to generate new peptide sequences:

Design and predict the structure and stability of peptides

Predict their binding to target proteins, and

Optimize their properties for the intended therapeutic applications.

Ready to make the first step towards your new future?

We’re here to help.

Contact Us